Tag: Hutchison China MediTech

November 29, 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

Hutchison China MediTech (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib...
November 26, 2018

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate)

Hutchison China MediTech (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate) with the initiation of product...
November 16, 2018

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

Hutchison China MediTech (AIM/Nasdaq: HCM) today announces the outcome of FALUCA, its Phase III trial of fruquintinib in advanced non-small cell lung cancer patients...
October 18, 2018

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

Hutchison China MediTech (AIM/Nasdaq:HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in combination...
September 5, 2018

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

Hutchison China MediTech (AIM/Nasdaq: HCM) today announces that fruquintinib capsules have been granted approval for drug registration by the National...